Every material Form 8-K Quest Diagnostics filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Quest Diagnostics reported third-quarter 2025 revenue of $2.82 billion, up 13.1% from a year earlier, and reported diluted EPS of $2.16, up 8.5%. The company raised its full-year 2025 revenue and adjusted diluted EPS guidance, but its reported diluted EPS range was lowered at both ends.
Q3 2025 net revenues of $2.82 billion, up 13.1%, including 6.8% organic growth; adjusted diluted EPS of $2.60, up 13.0%
Full-year 2025 net revenue guidance raised to $10.96 billion to $11.00 billion from $10.80 billion to $10.92 billion
Full-year reported diluted EPS guidance now $8.58 to $8.66, versus $8.60 to $8.80 previously; adjusted diluted EPS guidance raised to $9.76 to $9.84 from $9.63 to $9.83
Agreement with Corewell Health to form a lab services joint venture in Michigan; Co-Lab Solutions annual revenues expected to reach about $1 billion next year
Quest Diagnostics reported second-quarter 2025 revenue of $2.76 billion, up 15.2% from a year earlier, and reported diluted EPS of $2.47, up 21.7%. The company raised its adjusted full-year 2025 EPS outlook to $9.63-$9.83 and its net revenue outlook to $10.80 billion-$10.92 billion, but narrowed its reported EPS outlook to $8.60-$8.80, which is lower than the prior $8.62-$8.87 range.
Q2 2025 net revenues $2.76 billion, up 15.2%; organic revenues grew 5.2%, per the CEO's statement
Q2 diluted EPS $2.47 vs. $2.03 a year earlier; adjusted diluted EPS $2.62 vs. $2.35
Full-year 2025 adjusted diluted EPS raised to $9.63-$9.83 from $9.55-$9.80; reported diluted EPS lowered to $8.60-$8.80 from $8.62-$8.87
Year-to-date cash from operations $858 million, up 67.1%
Quest Diagnostics reported first quarter 2025 revenue of $2.65 billion, up 12.1% from a year earlier, and reported diluted EPS of $1.94, up 12.8%. The company raised its full-year 2025 reported diluted EPS outlook to $8.62 to $8.87 from $8.34 to $8.59 and reaffirmed its revenue and adjusted EPS guidance, which matters to shareholders because the earnings outlook moved up while the top-line outlook held.
Q1 2025 net revenues $2.65 billion, up 12.1%; organic requisition volume fell 0.9%
Reported diluted EPS $1.94, up 12.8%; adjusted diluted EPS $2.21, up 8.3%
Full-year 2025 reported diluted EPS now expected at $8.62 to $8.87, up from $8.34 to $8.59
Full-year 2025 revenue guidance of $10.70 billion to $10.85 billion and adjusted diluted EPS of $9.55 to $9.80 unchanged
Quest Diagnostics reported fourth quarter 2024 revenue of $2.62 billion, up 14.5%, and reported diluted EPS of $1.95, up 14.7%, with full year revenue of $9.87 billion, up 6.7%. The company gave 2025 reported diluted EPS guidance of $8.34 to $8.59 and raised its quarterly dividend 6.7% to $0.80 per share. Shareholders see higher reported earnings in 2024, a 2025 outlook above the 2024 reported EPS of $7.69, and a larger dividend.
Q4 2024 reported diluted EPS $1.95 vs. $1.70 in Q4 2023; adjusted diluted EPS $2.23, up 3.7%
Full year 2024 revenue $9.87 billion, up 6.7%; full year reported diluted EPS $7.69, up 2.7%
2025 reported diluted EPS guidance $8.34 to $8.59; adjusted diluted EPS guidance $9.55 to $9.80
Quarterly dividend raised from $0.75 to $0.80 per share, payable April 21, 2025, record date April 7, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Quest Diagnostics filing is on SEC EDGAR ↗. 8-K briefs of other companies →